Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Minority Interest (2016 - 2025)

Arrowhead Pharmaceuticals' Minority Interest history spans 15 years, with the latest figure at -$5.7 million for Q4 2025.

  • For Q4 2025, Minority Interest fell 264.23% year-over-year to -$5.7 million; the TTM value through Dec 2025 reached -$5.7 million, down 264.23%, while the annual FY2025 figure was $37.4 million, 564.96% up from the prior year.
  • Minority Interest reached -$5.7 million in Q4 2025 per ARWR's latest filing, down from $37.4 million in the prior quarter.
  • In the past five years, Minority Interest ranged from a high of $37.4 million in Q3 2025 to a low of -$5.7 million in Q4 2025.
  • Average Minority Interest over 4 years is $12.2 million, with a median of $13.3 million recorded in 2023.
  • The largest YoY upside for Minority Interest was 564.96% in 2025 against a maximum downside of 264.23% in 2025.
  • A 4-year view of Minority Interest shows it stood at $19.3 million in 2022, then crashed by 31.17% to $13.3 million in 2023, then crashed by 73.8% to $3.5 million in 2024, then tumbled by 264.23% to -$5.7 million in 2025.
  • Per Business Quant, the three most recent readings for ARWR's Minority Interest are -$5.7 million (Q4 2025), $37.4 million (Q3 2025), and -$2.5 million (Q2 2025).